Trending...
- Pregis Expands Wind Energy Use, Advancing Progress Toward Net Zero by 2040
- Yoga Retreats, Ecstatic Dance & Spiritual App launched
- Chicago: Mayor Brandon Johnson Statement on the Firing of Kristi Noem
CHICAGO, June 22, 2025 ~ A new dual agonist, CagriSema, has shown promising results in improving weight loss for patients with and without type 2 diabetes who have overweight or obesity. The findings were presented at the 85th Scientific Sessions of the American Diabetes Association® (ADA) in Chicago and simultaneously published in the New England Journal of Medicine.
According to recent studies, nearly 90% of adults in the United States who have diabetes also have overweight or obesity. This highlights the strong connection between excess weight and the development or progression of type 2 diabetes. While there have been advancements in treatment options for obesity and type 2 diabetes with glucagon-like peptide-1 (GLP-1) receptor agonists, there is still a need for therapies that can address both weight and glucose management simultaneously.
CagriSema, a dual agonist that targets both appetite control and glucose regulation, aims to fill this gap. The drug is a once-weekly combination of semaglutide and cagrilintide, two weight-loss medications.
More on illi News
The effectiveness and safety of CagriSema were evaluated in two phase 3 studies known as REDEFINE 1 and REDEFINE 2. REDEFINE 1 included 3,400 adults without diabetes but with at least one weight-related health condition such as high blood pressure or heart disease. Participants were randomly assigned to receive CagriSema, semaglutide, cagrilintide, or placebo. On the other hand, REDEFINE 2 enrolled 1,200 adults with type 2 diabetes who received either CagriSema or placebo.
Both studies met their goals by demonstrating significant weight loss with once-weekly CagriSema compared to placebo. In REDEFINE 1, participants lost an average of 20.4% of their body weight at week 68 with CagriSema compared to only 3% with placebo. When considering full treatment adherence, weight loss with CagriSema increased to 22.7%, and 40.4% of participants achieved at least 25% weight loss. Similarly, in REDEFINE 2, participants lost an average of 13.7% of their body weight at week 68 with CagriSema compared to only 3.4% with placebo. When accounting for all study participants who adhered to treatment, weight loss with CagriSema rose to 15.7%, while only 3.1% was seen in the placebo group.
More on illi News
The safety profile of CagriSema was consistent with other GLP-1 receptor agonists, with mild-to-moderate gastrointestinal issues being the most common side effects.
Professor Melanie Davies from the University of Leicester commented on the findings, stating that they represent a significant step forward in expanding treatment options for people living with obesity and type 2 diabetes. She emphasized the importance of developing therapies that not only promote meaningful weight loss but also improve glucose control, giving patients more tools to manage their health effectively.
The researchers involved in this study note that it is part of a larger REDEFINE program that aims to evaluate the effectiveness of CagriSema across different populations and inform future regulatory submissions.
The findings were presented by Professor Davies and Dr. Timothy Garvey at a symposium during the ADA's Scientific Sessions on June 22nd at 8:00 a.m CT. The presentation focused on the efficacy and safety of CagriSema in adults with overweight or obesity based on data from REDEFINE 1 and REDEFINE 2 clinical trials.
According to recent studies, nearly 90% of adults in the United States who have diabetes also have overweight or obesity. This highlights the strong connection between excess weight and the development or progression of type 2 diabetes. While there have been advancements in treatment options for obesity and type 2 diabetes with glucagon-like peptide-1 (GLP-1) receptor agonists, there is still a need for therapies that can address both weight and glucose management simultaneously.
CagriSema, a dual agonist that targets both appetite control and glucose regulation, aims to fill this gap. The drug is a once-weekly combination of semaglutide and cagrilintide, two weight-loss medications.
More on illi News
- The "Unsexy" Business Quietly Creating 130+ New Entrepreneurs Across America — From Alaska to Puerto Rico
- Veteran Launches GTG Energy: Nicotine-Free Pouch as Americans Rethink Addiction, Focus, and What Fuels Performance
- Midwest Microbrew Spotlights Nik and Ivy Brewing's Community Craft
- RecallSentry™ App Launch — Your Home Safety Hub — Free on iOS & Android
- Award-Winning Director Crystal J. Huang's Under-$50K Film "The Ritual House" Wins Best Horror Feature at Golden State Film Festival
The effectiveness and safety of CagriSema were evaluated in two phase 3 studies known as REDEFINE 1 and REDEFINE 2. REDEFINE 1 included 3,400 adults without diabetes but with at least one weight-related health condition such as high blood pressure or heart disease. Participants were randomly assigned to receive CagriSema, semaglutide, cagrilintide, or placebo. On the other hand, REDEFINE 2 enrolled 1,200 adults with type 2 diabetes who received either CagriSema or placebo.
Both studies met their goals by demonstrating significant weight loss with once-weekly CagriSema compared to placebo. In REDEFINE 1, participants lost an average of 20.4% of their body weight at week 68 with CagriSema compared to only 3% with placebo. When considering full treatment adherence, weight loss with CagriSema increased to 22.7%, and 40.4% of participants achieved at least 25% weight loss. Similarly, in REDEFINE 2, participants lost an average of 13.7% of their body weight at week 68 with CagriSema compared to only 3.4% with placebo. When accounting for all study participants who adhered to treatment, weight loss with CagriSema rose to 15.7%, while only 3.1% was seen in the placebo group.
More on illi News
- Grads aren't getting hired — here's what we're doing about it
- K2 Integrity Enhances Technology Capabilities Through Acquisition of Leviathan Security Group
- #WeAreGreekWarriors Comes to Detroit in Celebration of Women's History Month
- Mayor Brandon Johnson, DFSS Announce Rebranded "Chicago Youth Works" Youth Employment Initiative, Celebrate Kickoff of Summer Application Period
- Chicago: Mayor Brandon Johnson and BACP Announce the Delegate Agency for the South Lawndale Small Business Storefront Activation Program
The safety profile of CagriSema was consistent with other GLP-1 receptor agonists, with mild-to-moderate gastrointestinal issues being the most common side effects.
Professor Melanie Davies from the University of Leicester commented on the findings, stating that they represent a significant step forward in expanding treatment options for people living with obesity and type 2 diabetes. She emphasized the importance of developing therapies that not only promote meaningful weight loss but also improve glucose control, giving patients more tools to manage their health effectively.
The researchers involved in this study note that it is part of a larger REDEFINE program that aims to evaluate the effectiveness of CagriSema across different populations and inform future regulatory submissions.
The findings were presented by Professor Davies and Dr. Timothy Garvey at a symposium during the ADA's Scientific Sessions on June 22nd at 8:00 a.m CT. The presentation focused on the efficacy and safety of CagriSema in adults with overweight or obesity based on data from REDEFINE 1 and REDEFINE 2 clinical trials.
Filed Under: Business
0 Comments
Latest on illi News
- Quadcode Acquires Significant Stake in Game 7, LLC - The Parent Company for FPFX Tech and PropAccount.com
- Night Shade Introduces Smart Privacy Protection for Modern Devices
- Innovative Ear Muff Hat Combines Warmth and Convenience in One Winter Accessory
- Danholm Collection Announces Sale of 16689 Broadwater Ave in Winter Garden, Highlighting Strong Performance in Twinwaters Community
- New Repositionable Handheld Easel Offers Artists Greater Freedom and Flexibility
- Strong Clinical Results for Breakthrough Liver Diagnostic Platform; ENDRA Life Sciences (N A S D A Q: NDRA) $NDRA
- 46th International Symposium On Forecasting – Dates, Venue And Speakers Announced
- Phoenix Rebellion Therapy Celebrates 10 Years Helping Utahns Overcome Trauma as Utah Faces Nation's 2nd-Highest Rate of Mental Health Challenges
- Greater Englewood Chamber of Commerce to Host Member Meeting on March 11, 2026
- Bonavita Luxury & Portable Lavatories Announces Rebrand to Bonavita Site Solutions
- Raleigh Emerges as a Key Player in Sustainable Fashion Innovation for 2026
- Notice: Hrm Queen Laurence I Assumes Crown Control & $317q Fund. 3bn Unopoly Shares Settled. Requisition Of Buckingham Palace & Windsor Castle Final
- 13 Full Moons of Black Dandelion Convergent Voice™ An Integration of Literacy & Wellness Symposium
- Yoga Retreats, Ecstatic Dance & Spiritual App launched
- Elder Abuse Case Against Healthy Traditions Owner Raises Questions As To The Dire Reality Of Abuse Against The Last Of The Baby Boomers
- Janie's Art Journals Celebrates Women's History Month
- Simpalm Staffing Services Launched its Refreshed Website for Remote Staffing Services
- Claude Riveloux Review 2026: How the $10B Fund Manager Dispels 'Scam' Rumors Through Education
- Pure Energy Electrical Services, LLC Announces Strong Start to 2026, Reinforcing Customer-First Electrical Service Across Northeast Florida
- Danholm Collection Launches Boutique Luxury Real Estate Brokerage in Central Florida